INVERNESS MEDICAL INNOVATIONS ANNOUNCES
CLOSING OF WAMPOLE LABORATORIES ACQUISITION
______________________________________
Company Also Completes $35 Million Private Placements of Subordinated Debt and Converts a Substantial Amount of Series A Convertible Preferred Stock
WALTHAM, MA…September 23, 2002…Inverness Medical Innovations, Inc. (AMEX: IMA), a leading provider of women’s health and nutritional products and a developer of advanced medical devices, announced that it has closed its previously announced proposed acquisition of the Wampole Laboratories unit of MedPointe, Inc. for an aggregate purchase price of $70 million in cash. In completing the transaction, the company also completed two private placements of subordinated debt resulting in aggregate gross proceeds of approximately $35 million.
In the first of these private placements, the Company sold approximately $20 million of subordinated notes with warrants. The subordinated notes bear interest at 10% and mature in six years. The warrants issued in this placement represent the rights to acquire an aggregate of 160,000 shares of common stock at $13.54 per share. Directors and officers purchased an aggregate of $1,850,000 of the subordinated notes in this placement, of which $1,150,000 was purchased by an entity affiliated with Ron Zwanziger, CEO of the Company.
The second placement raised $15 million of gross proceeds through the sale of $9 million of subordinated notes and $6 million of convertible subordinated notes. The subordinated notes and convertible subordinated notes issued in the second placement bear interest at 9% and 3%, respectively, and mature in six years. The convertible subordinated notes convert into shares of common stock at an initial conversion price of $17.45. Entities associated with Mr. Zwanziger purchased an aggregate of $7.5 million of subordinated notes in the second placement. In connection with this second placement, holders of approximately 1.7 million shares of the company’s outstanding Series A Convertible Preferred Stock, representing approximately 84% of the total outstanding Series A Convertible Preferred Stock, voluntarily converted their preferred stock into common stock.
Additional detail and information regarding these transactions will be available in a Current Report on Form 8-K filing to be made by the company with the Securities and Exchange Commission. For more information about Inverness Medical Innovations, please visit our website at www.invernessmedical.com.
Inverness Medical Innovations manufactures and sells products for the women's health market, and is engaged in the business of developing, acquiring, manufacturing, and marketing advanced medical device technologies. The Company is presently exploring new opportunities for its proprietary electrochemical and other technologies in a variety of consumer-oriented applications including immuno-diagnostics with a focus on women's health and cardiology. The Company's women's health and nutritional products are distributed to consumers through established retail distribution networks such as Wal-Mart, Walgreens and CVS. Inverness is headquartered in Waltham, Massachusetts. |
